These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 30799262)

  • 41. Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinics.
    Varesco L; Viassolo V; Viel A; Gismondi V; Radice P; Montagna M; Alducci E; Della Puppa L; Oliani C; Tommasi S; Caligo MA; Vivanet C; Zuradelli M; Mandich P; Tibiletti MG; Cavalli P; Lucci Cordisco E; Turchetti D; Boggiani D; Bracci R; Bruzzi P; Bonelli L
    Breast; 2013 Dec; 22(6):1130-5. PubMed ID: 24011770
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Machine learning techniques for personalized breast cancer risk prediction: comparison with the BCRAT and BOADICEA models.
    Ming C; Viassolo V; Probst-Hensch N; Chappuis PO; Dinov ID; Katapodi MC
    Breast Cancer Res; 2019 Jun; 21(1):75. PubMed ID: 31221197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO.
    Biswas S; Tankhiwale N; Blackford A; Barrera AM; Ready K; Lu K; Amos CI; Parmigiani G; Arun B
    Breast Cancer Res Treat; 2012 May; 133(1):347-55. PubMed ID: 22270937
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Limited family structure and BRCA gene mutation status in single cases of breast cancer.
    Weitzel JN; Lagos VI; Cullinane CA; Gambol PJ; Culver JO; Blazer KR; Palomares MR; Lowstuter KJ; MacDonald DJ
    JAMA; 2007 Jun; 297(23):2587-95. PubMed ID: 17579227
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model.
    Terkelsen T; Christensen LL; Fenton DC; Jensen UB; Sunde L; Thomassen M; Skytte AB
    Fam Cancer; 2019 Oct; 18(4):381-388. PubMed ID: 31435815
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combining Breast Cancer Risk Prediction Models.
    Guan Z; Huang T; McCarthy AM; Hughes K; Semine A; Uno H; Trippa L; Parmigiani G; Braun D
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831433
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Validation of Breast Cancer Risk Models by Race/Ethnicity, Family History and Molecular Subtypes.
    McCarthy AM; Liu Y; Ehsan S; Guan Z; Liang J; Huang T; Hughes K; Semine A; Kontos D; Conant E; Lehman C; Armstrong K; Braun D; Parmigiani G; Chen J
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008209
    [TBL] [Abstract][Full Text] [Related]  

  • 48. iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management.
    Collins IM; Bickerstaffe A; Ranaweera T; Maddumarachchi S; Keogh L; Emery J; Mann GB; Butow P; Weideman P; Steel E; Trainer A; Bressel M; Hopper JL; Cuzick J; Antoniou AC; Phillips KA
    Breast Cancer Res Treat; 2016 Feb; 156(1):171-82. PubMed ID: 26909793
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Model for individualized prediction of breast cancer risk after a benign breast biopsy.
    Pankratz VS; Degnim AC; Frank RD; Frost MH; Visscher DW; Vierkant RA; Hieken TJ; Ghosh K; Tarabishy Y; Vachon CM; Radisky DC; Hartmann LC
    J Clin Oncol; 2015 Mar; 33(8):923-9. PubMed ID: 25624442
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validation of the International Breast Cancer Intervention Study (IBIS) model in the High Risk Ontario Breast Screening Program: A retrospective cohort study.
    Brooks JD; Mah A; Christensen RAG; Arneja J; Eisen A; Chiarelli AM
    Genet Med; 2023 Jun; 25(6):100820. PubMed ID: 36919844
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort.
    Lakeman IMM; Rodríguez-Girondo M; Lee A; Ruiter R; Stricker BH; Wijnant SRA; Kavousi M; Antoniou AC; Schmidt MK; Uitterlinden AG; van Rooij J; Devilee P
    Genet Med; 2020 Nov; 22(11):1803-1811. PubMed ID: 32624571
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of mathematical models for breast cancer risk assessment in routine clinical use.
    Fasching PA; Bani MR; Nestle-Krämling C; Goecke TO; Niederacher D; Beckmann MW; Lux MP
    Eur J Cancer Prev; 2007 Jun; 16(3):216-24. PubMed ID: 17415092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients.
    Rao NY; Hu Z; Yu JM; Li WF; Zhang B; Su FX; Wu J; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 Aug; 116(3):563-70. PubMed ID: 18807178
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Performance of Breast Cancer Risk-Assessment Models in a Large Mammography Cohort.
    McCarthy AM; Guan Z; Welch M; Griffin ME; Sippo DA; Deng Z; Coopey SB; Acar A; Semine A; Parmigiani G; Braun D; Hughes KS
    J Natl Cancer Inst; 2020 May; 112(5):489-497. PubMed ID: 31556450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Validation of a breast cancer risk prediction model developed for Black women.
    Boggs DA; Rosenberg L; Pencina MJ; Adams-Campbell LL; Palmer JR
    J Natl Cancer Inst; 2013 Mar; 105(5):361-7. PubMed ID: 23411594
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Accuracy of the BRCAPRO model among women with bilateral breast cancer.
    Ready KJ; Vogel KJ; Atchley DP; Broglio KR; Solomon KK; Amos C; Lu KH; Hortobagyi GN; Arun B
    Cancer; 2009 Feb; 115(4):725-30. PubMed ID: 19127556
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
    Antonucci I; Provenzano M; Sorino L; Balsamo M; Aceto GM; Battista P; Euhus D; Cianchetti E; Ballerini P; Natoli C; Palka G; Stuppia L
    J Hum Genet; 2017 Mar; 62(3):379-387. PubMed ID: 27928164
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparing 5-Year and Lifetime Risks of Breast Cancer using the Prospective Family Study Cohort.
    MacInnis RJ; Knight JA; Chung WK; Milne RL; Whittemore AS; Buchsbaum R; Liao Y; Zeinomar N; Dite GS; Southey MC; Goldgar D; Giles GG; Kurian AW; ; Andrulis IL; John EM; Daly MB; Buys SS; Phillips KA; Hopper JL; Terry MB
    J Natl Cancer Inst; 2021 Jun; 113(6):785-791. PubMed ID: 33301022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Validation of three BRCA1/2 mutation-carrier probability models Myriad, BRCAPRO and BOADICEA in a population-based series of 183 German families.
    Schneegans SM; Rosenberger A; Engel U; Sander M; Emons G; Shoukier M
    Fam Cancer; 2012 Jun; 11(2):181-8. PubMed ID: 22160602
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.